SBRT as a Vaccination for Metastatic Melanoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 26, 2019

Primary Completion Date

November 26, 2019

Study Completion Date

January 26, 2021

Conditions
Metastatic Melanoma
Interventions
DRUG

Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]

480mg IV every 4 weeks

RADIATION

Stereotactic Body Radiation Therapy (SBRT)

SBRT dose of 8-10 Gy x 3 fractions (at maximum 3 doses per week) delivered to 1 extracranial site between days 1-14 of Cycle 1.

Trial Locations (2)

21224

Johns Hopkins Bayview, Baltimore

21231

The Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER